In this study, the effect of novel MDM2 inhibitor APG-115 disrupting the interaction of MDM2-p53 and restoration of p53 expression was first explored in TP53-wild type CLL patient primary cells and EHEB cells. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.